A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +6 locations
Conditions: High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Register for Updates
Study to Assess the Safety, Tolerability, PK and PD of ABX1100
NCT06109948
Recruiting
Study ABX1100-1001 is a first-in-human (FIH), phase 1 study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose (SAD) and multiple doses (MD) of ABX1100 administered intravenously to healthy participants and patients with LOPD. * Part A features a SAD study with a double-blind, placebo-controlled, randomized design in NHVs involving 3 cohorts (A1-A3). This Part also includes a single dose, open-labeled cohort (A4) in NHVs which will commence afte... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: UCI, Orange, California +4 locations
Conditions: Healthy, Late Onset Pompe Disease
Register for Updates
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479
Recruiting
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Local Institution - 0071, Birmingham, Alabama +125 locations
Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
Register for Updates
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752
Recruiting
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
07/29/2025
Locations: Highlands Oncology Group, Fayetteville, Arkansas +5 locations
Conditions: Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Register for Updates
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069
Recruiting
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form... Read More
Gender:
ALL
Ages:
Between 180 days and 22 years
Trial Updated:
07/29/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +102 locations
Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Register for Updates
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
NCT05286801
Recruiting
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as tiragolumab and atezolizumab, may help the body's immune... Read More
Gender:
ALL
Ages:
12 months and above
Trial Updated:
07/29/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +39 locations
Conditions: Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Rhabdoid Tumor, Rhabdoid Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Register for Updates
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
NCT03242642
Recruiting
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Alabama Birmingham (UAB), Birmingham, Alabama +84 locations
Conditions: Mitral Valve Regurgitation
Register for Updates
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941
Recruiting
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/29/2025
Locations: Arizona Arthritis and Rheumatology Research PLLC, Mesa, Arizona +52 locations
Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Register for Updates
Low Versus Standard Pressure Pneumoperitoneum on Shoulder Tip Pain
NCT06504277
Recruiting
This proposed study is a single-center, double blind, parallel group RCT comparing the use of low (10 mm Hg) versus standard pressure (15 mm Hg) pneumoperitoneum at the time of benign gynecologic laparoscopic surgery. Patients will be randomized to the control group (standard pressure) or the intervention group (low pressure) and surgeons will be blinded to the study pressure. Data on post-operative recovery and pain scores will be recorded for each patient.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Women's College Hospital, Toronto, Ontario
Conditions: Surgery, Laparoscopic, Laparoscopy, Penumoperitoneum, Post-operative Pain, Post-operative Recovery
Register for Updates
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706
Recruiting
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/28/2025
Locations: Aclaris Study Site, Bryant, Arkansas +22 locations
Conditions: Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Register for Updates
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416
Recruiting
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be app... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Banner Gateway Medical Center, Gilbert, Arizona +221 locations
Conditions: Multiple Myeloma
Register for Updates
Methoxyflurane for IUD Insertion and Endometrial Biopsy
NCT07046572
Recruiting
The aim of this study is to determine if 3ml of inhaled Methoxyflurane, in the form of a Penthrox inhaler, reduces pain during IUD insertion and/or endometrial biopsy. The proposed study is a double-blind, placebo-controlled RCT. Each participant will be randomly assigned to one of two arms: 1. Intervention (3ml of Methoxyflurane via a Penthrox inhaler) 2. Placebo (3ml of normal saline via an identical placebo Penthrox inhaler) The primary outcome is global pain score, which will be patient-r... Read More
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
07/28/2025
Locations: OPG, Toronto, Ontario
Conditions: Endometrial Biopsy, Intrauterine Devices
Register for Updates